FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996837305> ?p ?o ?g. }

• W1996837305 abstract "Canagliflozin is a sodium glucose co-transporter 2 inhibitor developed for the treatment of patients with type 2 diabetes mellitus (T2DM). The efficacy and safety of canagliflozin were evaluated in patients with T2DM <65 and ≥65 years of age. Pooled data from 4 randomised, placebo-controlled, 26-week, Phase 3 studies (N = 2,313) evaluating canagliflozin 100 and 300 mg were analysed by age: <65 years (n = 1,868; mean age, 52.8 years) or ≥65 years (n = 445; mean age, 69.3 years). Efficacy evaluations included change from baseline in glycaemic parameters and systolic blood pressure (BP), and percent change from baseline in body weight. Assessment of safety/tolerability included adverse event (AE) reports, incidence of documented hypoglycaemia, and percent change from baseline in fasting plasma lipids. Canagliflozin 100 and 300 mg reduced HbA1c and fasting plasma glucose relative to placebo in patients <65 and ≥65 years of age. Both canagliflozin doses reduced body weight and systolic BP relative to placebo in patients <65 and ≥65 years of age. Incidence of overall AEs was similar across all treatment groups in patients <65 and ≥65 years of age. Incidences of serious AEs and AE-related discontinuations were similar across all treatment groups in patients <65 years of age and higher with canagliflozin 100 mg than other groups in patients ≥65 years of age. As in patients <65 years of age, incidences of genital mycotic infections and osmotic diuresis-related AEs were higher with canagliflozin relative to placebo in those ≥65 years of age. Incidences of urinary tract infections (UTIs), renal-related AEs, AEs related to volume depletion, and documented hypoglycaemia episodes were similar across all treatment groups in patients ≥65 years of age; no notable trends were observed with canagliflozin 100 and 300 mg relative to placebo in these AEs among patients <65 years of age. Changes in lipid parameters with canagliflozin were similar in both age subsets. Canagliflozin improved glycaemic control, body weight, and systolic BP, and was generally well tolerated in older patients with T2DM. ClinicalTrials.gov, NCT01081834 ; NCT01106677 ; NCT01106625 ; NCT01106690 ." @default.
• W1996837305 created "2016-06-24" @default.
• W1996837305 creator A5004194306 @default.
• W1996837305 creator A5005036709 @default.
• W1996837305 creator A5007025699 @default.
• W1996837305 creator A5011599056 @default.
• W1996837305 creator A5026752543 @default.
• W1996837305 creator A5031542137 @default.
• W1996837305 creator A5038040018 @default.
• W1996837305 creator A5052004719 @default.
• W1996837305 creator A5061317385 @default.
• W1996837305 creator A5077346926 @default.
• W1996837305 date "2014-04-18" @default.
• W1996837305 modified "2023-10-10" @default.
• W1996837305 title "Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies" @default.
• W1996837305 cites W1968145432 @default.
• W1996837305 cites W1997018189 @default.
• W1996837305 cites W2021988691 @default.
• W1996837305 cites W2029486004 @default.
• W1996837305 cites W2038270027 @default.
• W1996837305 cites W2068171948 @default.
• W1996837305 cites W2074989651 @default.
• W1996837305 cites W2077038286 @default.
• W1996837305 cites W2084511068 @default.
• W1996837305 cites W2096721022 @default.
• W1996837305 cites W2110424396 @default.
• W1996837305 cites W2111876001 @default.
• W1996837305 cites W2120919346 @default.
• W1996837305 cites W2130570549 @default.
• W1996837305 cites W2135097670 @default.
• W1996837305 cites W2138835437 @default.
• W1996837305 cites W2149971684 @default.
• W1996837305 cites W2167984652 @default.
• W1996837305 cites W2168926920 @default.
• W1996837305 doi "https://doi.org/10.1186/1472-6823-14-37" @default.
• W1996837305 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4021426" @default.
• W1996837305 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24742013" @default.
• W1996837305 hasPublicationYear "2014" @default.
• W1996837305 type Work @default.
• W1996837305 sameAs 1996837305 @default.
• W1996837305 citedByCount "77" @default.
• W1996837305 countsByYear W19968373052014 @default.
• W1996837305 countsByYear W19968373052015 @default.
• W1996837305 countsByYear W19968373052016 @default.
• W1996837305 countsByYear W19968373052017 @default.
• W1996837305 countsByYear W19968373052018 @default.
• W1996837305 countsByYear W19968373052019 @default.
• W1996837305 countsByYear W19968373052020 @default.
• W1996837305 countsByYear W19968373052021 @default.
• W1996837305 countsByYear W19968373052022 @default.
• W1996837305 countsByYear W19968373052023 @default.
• W1996837305 crossrefType "journal-article" @default.
• W1996837305 hasAuthorship W1996837305A5004194306 @default.
• W1996837305 hasAuthorship W1996837305A5005036709 @default.
• W1996837305 hasAuthorship W1996837305A5007025699 @default.
• W1996837305 hasAuthorship W1996837305A5011599056 @default.
• W1996837305 hasAuthorship W1996837305A5026752543 @default.
• W1996837305 hasAuthorship W1996837305A5031542137 @default.
• W1996837305 hasAuthorship W1996837305A5038040018 @default.
• W1996837305 hasAuthorship W1996837305A5052004719 @default.
• W1996837305 hasAuthorship W1996837305A5061317385 @default.
• W1996837305 hasAuthorship W1996837305A5077346926 @default.
• W1996837305 hasBestOaLocation W19968373051 @default.
• W1996837305 hasConcept C120665830 @default.
• W1996837305 hasConcept C121332964 @default.
• W1996837305 hasConcept C126322002 @default.
• W1996837305 hasConcept C134018914 @default.
• W1996837305 hasConcept C142724271 @default.
• W1996837305 hasConcept C197934379 @default.
• W1996837305 hasConcept C204787440 @default.
• W1996837305 hasConcept C27081682 @default.
• W1996837305 hasConcept C2777451236 @default.
• W1996837305 hasConcept C2778375690 @default.
• W1996837305 hasConcept C2910068830 @default.
• W1996837305 hasConcept C555293320 @default.
• W1996837305 hasConcept C61511704 @default.
• W1996837305 hasConcept C71924100 @default.
• W1996837305 hasConcept C84393581 @default.
• W1996837305 hasConceptScore W1996837305C120665830 @default.
• W1996837305 hasConceptScore W1996837305C121332964 @default.
• W1996837305 hasConceptScore W1996837305C126322002 @default.
• W1996837305 hasConceptScore W1996837305C134018914 @default.
• W1996837305 hasConceptScore W1996837305C142724271 @default.
• W1996837305 hasConceptScore W1996837305C197934379 @default.
• W1996837305 hasConceptScore W1996837305C204787440 @default.
• W1996837305 hasConceptScore W1996837305C27081682 @default.
• W1996837305 hasConceptScore W1996837305C2777451236 @default.
• W1996837305 hasConceptScore W1996837305C2778375690 @default.
• W1996837305 hasConceptScore W1996837305C2910068830 @default.
• W1996837305 hasConceptScore W1996837305C555293320 @default.
• W1996837305 hasConceptScore W1996837305C61511704 @default.
• W1996837305 hasConceptScore W1996837305C71924100 @default.
• W1996837305 hasConceptScore W1996837305C84393581 @default.
• W1996837305 hasIssue "1" @default.
• W1996837305 hasLocation W19968373051 @default.
• W1996837305 hasLocation W19968373052 @default.
• W1996837305 hasLocation W19968373053 @default.
• W1996837305 hasLocation W19968373054 @default.
• W1996837305 hasOpenAccess W1996837305 @default.
• W1996837305 hasPrimaryLocation W19968373051 @default.

• next